Emet Surgical

Transforming Minimally Invasive Surgery from Experience Dependent to Data Enhanced

Startup

Emet Surgical is a Tel Aviv-Yafo-based startup in the Health Tech & Life Sciences sector, established in 2021. Transforming Minimally Invasive Surgery from Experience Dependent to Data Enhanced. The company has raised a total of $1.3M across 3 funding rounds, currently at the Pre-Seed stage. Emet Surgical was founded by Bob Witkow. Key investors include Bob Witkow. The company has 1-10 employees. Core technologies: Artificial Intelligence, Sensing, Machinery & Robotics, Simulation & Imaging.

With $1.3M in total funding, Emet Surgical is a Pre-Seed-stage company operating in Health Tech & Life Sciences. The company follows a B2B business model. Product stage: Alpha. The company holds 1 patent.

$1.3M
Raised
3
Rounds
1
Investors
2
Team
2021
Founded
1
Patents
Sector & Technology
Health Tech & Life SciencesDigital HealthcareMedical DevicesArtificial IntelligenceSensingMachinery & RoboticsSimulation & Imaging
At a Glance
Investors
Founders
In the News

1 article covered by sources including www.businesswire.com.

www.businesswire.com · Apr 18, 2023
Emet Surgical Aspires to Improve Surgery Outcomes by Enabling True Collaboration Between Cancer Surgeons and Pathologists
Read article ↗
Frequently Asked Questions
What does Emet Surgical do?

Emet Surgical is redefining minimally invasive surgery with ESP – the Enhanced Surgical Precision system, an AI/ML-powered platform that provides real-time surgical guidance and cancerous tissue recognition. Founded by cancer survivor and tech entrepreneur Bob Witkow, and developed in consultation with experienced surgeons, ESP supports—rather than replaces—surgeons’ expertise. It delivers real-time, data-driven insights on the surgical video feed, enhancing precision and decision-making. Emet Surgical helps surgeons reduce complications and reoperations—persistent challenges despite decades of progress in surgical tools and techniques. The company also aims to reverse the measurable decline in incidental cancer detection since the shift from open to minimally invasive surgery. By improving visibility of critical structures and suspicious tissue in real time, ESP can improve outcomes and lower treatment costs. ESP works with any robotic or laparoscopic system and runs on proprietary technology, including IP developed internally and licensed from the University of Minnesota. Foundational research, funded largely by the U.S. National Science Foundation, gives Emet Surgical a deep scientific base with strong capital efficiency. ESP recently reached a milestone by identifying cancerous tissue in real time during video analysis—a key step toward clinical trials. Emet Surgical will launch ESP with cancer recognition, followed by advanced dissection guidance and hospital system integration. Regulatory submissions for FDA 510(k) SaMD, EU CE Mark, UKCA, and Israel AMAR are planned for Q4 2025 and Q1 2026. The company is raising capital to complete validation, secure regulatory approval, and enter the market. Investors in AI, surgical robotics, or digital health are invited to connect. Emet Surgical operates under the legal entities Emet Surgical Inc. (USA) and Emet Medical Devices Ltd. (Israel).

How much funding has Emet Surgical raised?

Emet Surgical has raised $1.3M in total funding across 3 rounds. The company is currently at the Pre-Seed stage. Key investors include Bob Witkow.

Who founded Emet Surgical?

Emet Surgical was founded in 2021 by Bob Witkow (Founder & CEO).

What sector is Emet Surgical in?

Emet Surgical operates in Health Tech & Life Sciences, Digital Healthcare, Medical Devices, with core technologies in Artificial Intelligence, Sensing, Machinery & Robotics, Simulation & Imaging. Target customers: Healthcare & Life Sciences, Healthcare, Providers.

Where is Emet Surgical located?

Emet Surgical is based in Derech Menachem Begin 146, Tel Aviv-Yafo, Israel. The company also has offices abroad.

View Full Profile Classic View Website ↗